GlassScriptPhysician profile
Meet A Kadakia
NPI 1023470713
$463.73
in general payments reported to CMS, 2019-2025
10 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.73 · 2021: $119 · 2023: $183 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $306 · Education: $15.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $306.27 |
| Education | $15.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $159.55 | 2023-2025 | Imdelltra (Amg757), Lumakras |
| Rigel Pharmaceuticals, INC. | $119.48 | 2021 | |
| Pfizer INC. | $38.17 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $27.89 | 2023 | Opdivo, Eliquis |
| Insmed, INC. | $22.73 | 2019 | |
| Abbvie INC. | $22.32 | 2023 | |
| Lilly USA, LLC | $21.96 | 2023 | Jaypirca, Verzenio |
| Merck Sharp & Dohme LLC | $21.63 | 2023 | Lynparza, Keytruda |
| Bayer Healthcare Pharmaceuticals INC. | $15.45 | 2023 | |
| Genentech USA, INC. | $14.55 | 2023 | Tecentriq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meet Kadakia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.